Nova Steroid Pharma Co.,Ltd
High-Quality STROMUSC Anavar(Oxandrolone)50mg For Bodybuilding CAS:53-39-4

High-Quality STROMUSC Anavar(Oxandrolone)50mg For Bodybuilding CAS:53-39-4

Oxandrolone, marketed under the trade name Anavar among others, represents one of the most extensively studied oral anabolic-androgenic steroids (AAS) in pharmaceutical history. First synthesized in 1962 by researchers at Searle Laboratories, this dihydrotestosterone (DHT) derivative was engineered with a specific molecular modification—an oxygen atom replacing the carbon-2 in the A-ring of the steroid nucleus. This subtle structural alteration fundamentally changed its metabolic fate, creating a compound with a markedly different therapeutic index compared to testosterone and its earlier derivatives.

Send Inquiry
Description

   Chemical Architecture and Pharmacological Identity

    At its core, Oxandrolone is a 17α-alkylated anabolic steroid, bearing the chemical designation 17β-hydroxy-17α-methyl-2-oxa-5α-androstan-3-one. The 17α-methylation was necessary to enable oral bioavailability; without this modification, hepatic first-pass metabolism would rapidly inactivate the molecule before it could exert systemic effects. The 2-oxa substitution, however, is what truly distinguishes Oxandrolone from its pharmacological cousins. By inserting an oxygen atom into the steroid backbone, chemists succeeded in separating anabolic activity from androgenic activity to a degree previously unattainable with earlier testosterone derivatives.

    This molecular configuration yields an anabolic-to-androgenic ratio that has been estimated at approximately 10:1 in preclinical models, though human metabolic variability renders such ratios approximate at best. What this translates to physiologically is a compound capable of promoting nitrogen retention and protein synthesis without producing the same magnitude of virilizing effects characteristic of more androgenic agents like methyltestosterone or fluoxymesterone.

1

2

Clinical Origins and Legitimate Medical Applications

    The FDA approved Oxandrolone for human use in 1964, and its initial therapeutic indications reflected the medical priorities of that era. It was prescribed to promote weight gain following extensive surgery, chronic infections, or severe trauma-clinical scenarios where catabolic states threatened patient recovery. Additionally, it found application in offsetting protein catabolism caused by prolonged corticosteroid administration, and in treating bone pain associated with osteoporosis.

    Perhaps its most enduring medical application has been in managing involuntary weight loss. Unlike many anabolic agents that produce primarily water and glycogen retention, Oxandrolone generates measurable gains in lean tissue mass, making it valuable in wasting syndromes. More recently, clinical research has explored its utility in burn recovery, where its ability to preserve lean body mass during hypermetabolic states has demonstrated measurable improvements in patient outcomes. The drug has also been utilized in treating Turner syndrome and, in some protocols, as an adjunct in HIV-related cachexia, though these applications require careful monitoring due to hepatotoxicity concerns.

Mechanism of Action and Physiological Effects

    Oxandrolone exerts its effects primarily through binding to androgen receptors (AR) located in skeletal muscle tissue, adipocytes, and various organ systems. Upon binding, the steroid-receptor complex translocates to the cell nucleus, where it interacts with androgen response elements on DNA, modulating the transcription of specific genes involved in protein synthesis. This genomic pathway operates on a timescale of hours to days, explaining why measurable physiological changes require sustained administration rather than single doses.

    Beyond direct genomic effects, Oxandrolone influences several secondary messenger systems. It upregulates creatine kinase activity in muscle cells, enhances erythropoietin production leading to increased red blood cell mass, and modulates thyroid-binding globulin levels, indirectly affecting metabolic rate. The compound also demonstrates a measurable suppressive effect on sex hormone-binding globulin (SHBG), which paradoxically can increase free testosterone concentrations when administered alongside exogenous testosterone preparations-a pharmacological interaction that has not gone unnoticed in non-medical contexts.

    The 50mg dosage threshold represents a significant pharmacological milestone. In clinical settings, therapeutic doses typically ranged from 2.5mg to 20mg daily, divided into multiple administrations. The 50mg figure emerged not from clinical necessity but from the dose-escalation patterns observed in non-medical use, where users sought supraphysiological effects beyond what conservative medical dosing could provide. At this concentration, the drug saturates androgen receptors more completely and produces measurable alterations in body composition, though simultaneously escalating the risk profile substantially.

Pharmacokinetics and Metabolic Disposition

    Understanding Oxandrolone's half-life is essential to comprehending its clinical behavior. The elimination half-life ranges between 9 and 10 hours in adult subjects, though individual variation in hepatic enzyme activity can extend or compress this window. This relatively brief half-life necessitates divided dosing schedules to maintain stable plasma concentrations-typically two to three administrations daily in therapeutic contexts.

    The compound undergoes extensive hepatic metabolism, primarily through hydroxylation and conjugation pathways. Unlike testosterone, Oxandrolone does not aromatize to estrogen due to its DHT-derived structure; the 2-oxa substitution further prevents 5α-reduction, meaning it does not convert to dihydrotestosterone metabolites. This characteristic eliminates certain side effects associated with estrogenic activity-specifically gynecomastia and significant water retention-while simultaneously meaning the drug does not provide the collagen synthesis and joint lubrication benefits sometimes attributed to estrogenic compounds.

    Because of its 17α-alkylated structure, Oxandrolone places measurable stress on hepatocellular integrity. Serum markers of liver function, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), frequently elevate during administration, though the clinical significance of these elevations varies considerably with dose and duration. Unlike some C-17 α-alkylated steroids that produce profound cholestatic injury, Oxandrolone's hepatotoxic profile is generally regarded as moderate, though this assessment applies to therapeutic doses rather than the supraphysiological regimens encountered in non-medical use.

The Bodybuilding Phenomenon: Context and Physiology

    The migration of Oxandrolone from clinical endocrinology to physique culture occurred gradually throughout the 1970s and 1980s. Bodybuilders gravitated toward the compound for several pharmacological reasons that merit objective examination. Its inability to aromatize meant that users could achieve hardened muscular appearance without the subcutaneous water retention that blurs muscular definition. The drug's potent effects on nitrogen retention-studies have documented significant improvements in nitrogen balance even in caloric deficit-made it attractive during pre-competition phases when athletes sought to preserve muscle mass while reducing adipose tissue.

    Furthermore, Oxandrolone exhibits a peculiar metabolic effect on adipose tissue. Research indicates it directly stimulates lipolysis in visceral and subcutaneous fat deposits through mechanisms involving the androgen receptor-mediated upregulation of lipolytic enzymes. This characteristic, combined with its relatively mild androgenic footprint, positioned it as an agent of choice among individuals seeking recomposition effects rather than pure mass accretion.

    The 50mg dosage commonly referenced in physique communities represents a substantial escalation from medical parameters. At this intake level, users report enhanced vascularity, increased muscular density, and measurable strength increments. However, these doses also amplify the suppressive effects on hypothalamic-pituitary-gonadal (HPG) axis function. Exogenous androgens deliver negative feedback to the hypothalamus, reducing gonadotropin-releasing hormone (GnRH) pulsatility, which cascades into diminished luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion from the anterior pituitary. The downstream consequence is testicular atrophy and suppressed endogenous testosterone production.

Post-Cycle Considerations and Endocrine Recovery

    The cessation of exogenous Oxandrolone administration triggers a variable recovery timeline for the HPG axis. Because the drug does not convert to estrogen, users do not face the same immediate estrogen rebound seen with aromatizing compounds. Nevertheless, the suppressed LH and FSH levels require time to normalize as the hypothalamus gradually resumes GnRH secretion. The duration of suppression correlates with cycle length and cumulative dose; higher doses and extended durations produce more profound and persistent axis shutdown.

    In legitimate medical contexts, physicians might employ human chorionic gonadotropin (hCG) to stimulate Leydig cell function or selective estrogen receptor modulators (SERMs) like Clomiphene citrate to block hypothalamic estrogen receptors and stimulate endogenous GnRH release. These interventions require medical supervision, as improper application can exacerbate hormonal dysfunction or produce thromboembolic complications.

Adverse Effect Profile and Long-Term Risks

    The safety margin of Oxandrolone narrows considerably at supraphysiological doses. Hepatic stress represents the most immediate concern, with case reports documenting peliosis hepatis, hepatic adenomas, and elevated hepatic enzyme levels. Dyslipidemia manifests predictably: high-density lipoprotein (HDL) cholesterol declines while low-density lipoprotein (LDL) cholesterol increases, creating an atherogenic lipid profile that elevates cardiovascular risk over time.

    Androgenic effects, though attenuated compared to other AAS, still occur with dose-dependent frequency. These include acne vulgaris, androgenetic alopecia in genetically susceptible individuals, and virilization in women. The 17α-alkylated structure also precludes the drug from being safely administered to patients with pre-existing hepatic pathology.

Clinical Data
Brand STROMUSC

Trade names

Oxandrin, Anavar, Oxandrolone

CAS

53-39-4

Molar mass

306.45

Formula

C19H30O3

Purity

Above 98%

Apprarance

50mg*100

 

 

Any needs, please contact us

Email: Jasonraws106@gmail.com

WhatsApp: +86-15572565525
Telegram: +86-15871669785

   

QQ20240306150406            product-948-1135                        product-521-245

 

Conclusion

    Oxandrolone remains a fascinating pharmacological entity-a steroid engineered through precise molecular modification to achieve therapeutic goals that transcended the capabilities of its chemical predecessors. Its 50mg presentation in contemporary discourse reflects not medical optimization but the escalation patterns of non-medical use. While its chemical properties genuinely promote protein synthesis, lipolysis, and nitrogen retention, these effects occur within a risk framework that includes hepatic stress, cardiovascular dyslipidemia, and endocrine suppression.

    The compound's legitimate medical applications in wasting syndromes, burn recovery, and catabolic states demonstrate genuine therapeutic value when administered under physician supervision with appropriate monitoring. However, the appropriation of this pharmaceutical for physique enhancement operates outside evidence-based medicine, exposing users to compounded health risks without the safeguard of clinical oversight. Any consideration of Oxandrolone administration requires thorough understanding not merely of its anabolic potential, but of its complete pharmacological profile-including the metabolic, endocrine, and hepatic consequences that accompany its use.

Hot Tags: high-quality stromusc anavar(oxandrolone)50mg for bodybuilding cas:53-39-4, China high-quality stromusc anavar(oxandrolone)50mg for bodybuilding cas:53-39-4 manufacturers, suppliers, factory

Inquiry
goTop

(0/10)

clearall